Cardiotoxicity of oncological treatment in children

Advances in Clinical and Experimental Medicine

Volumn 21, Issue 3, 2012, Pages 281-288

  Kucharska, Wioleta ^a   Negrusz Kawecka, Marta ^a   Gromkowska, Małgorzata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Anthracyclines cardiotoxicity; Chemotherapy; Children; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; NATRIURETIC FACTOR; RAZOXANE; TROPONIN;

ASYMPTOMATIC DISEASE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHILD; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; LUNG CANCER; LYMPHOMA; MEDIASTINUM TUMOR; MEDICAL SOCIETY; MYOCARDITIS; PATIENT MONITORING; PERICARDITIS; QT PROLONGATION; RESTRICTIVE CARDIOMYOPATHY; REVIEW; SINUS TACHYCARDIA; THORAX RADIOGRAPHY; THYMOMA;

EID: 84863757683     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Kowalczyk JR: Epidemiologia nowotworów złośliwych u dzieci. In: Onkologia i hematologia dzieciȩca. Eds.: Chybicka A, Sawicz-Birkowska K. Wydawnictwo Lekarskie PZWL, Warszawa 2008, 3-7.
2. Shankar SM, Marina N, Hudson MM, Hogdson DC, Adams J, Landier W, Bhatia S, Meeske K, Chen MH, Kinahan K, Steinberger J, Rosenthal D: Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics 2008, 121, 387-396.
3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kaddan-Lottick N, Schwartz CL, Leisenring W, Robinson LL: Chronic health conditions in adult survivors of childhood cancer. NEJM 2006, 12, 355, 1572-1582. (Pubitemid 44547808)
4. Brȩborowicz E, Brȩborowicz P, Litwiniuk M, Tomczak P: Anthracycline-induced cardiomyopathy, an essential diagnostic and therapeutic problem in oncological practice. Współcz Onkol 2007, 11, 204-209. (Pubitemid 47086197)
5. Młot B, Rzepecki P: Cardiotoxicity of oncological treatment. J Oncol 2010, 60, 536-547.
6. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG: Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of Cardiology Committee of the Children's Cancer Group. Pediatrics 1992, 89, 5, 942-949.
7. Deptała A, Omyła-Staszewska J, Staszewska- Skurczyńska M: Cardiotoxicity of anthracyclines and cardioprotection. Facts and myths. Współcz Onkol 2004, 8, 107-111.
8. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97, 2869-2879. (Pubitemid 36605157)
9. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324, 808-815.
10. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA: Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001, 19, 191-196. (Pubitemid 32063496)
11. Recommendations of National Team of Cardiologic and Oncologic Supervision on cardiologic safety of patients with breast cancer. The prevention and treatment of cardiovascular complications in breast cancer The Task Force of National Consultants in Cardiology and Clinical Oncology for the elaboration of recommendations of cardiologie proceeding with patients with breast cancer. Kardiol Pol 2011, 69, 520-530.
12. Grenier MA, Lipshultz SE: Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25, Suppl 10, 72-85. (Pubitemid 28460388)
13. Creutzig U, Diekamp S, Zimmermann M, Reinhardt D: Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007, 48, 651-662. (Pubitemid 46717611)
14. Blanco JG, Sun C, Landier W, Chen L, Oeffinger KC, Hudson MM, Neglia JP, Ritchey AK, Relling MV, Bhatia S: Anthracycline-related cardiomyopathy in childhood cancer with polymorphism in the carbonyl reductase genes: A Children Oncology Group Study. J Clin Oncol 2010, 28, 15 Suppl. 1, 681.
15. Dudka J, Burdan F, Korga A, Dyndor K, Syroka I, Ziȩba J, Lewkowicz D, Korobowicz-Markiewicz A: The diagnosis of anthracycline-induced cardiac damage and heart failure. Postȩpy Hig Med Dośw 2009, 63, 225-233.
16. Rola echokardiografii w chorobach ogólnoustrojowych i rozwia̧zywanie problemów klinicznych. In: Echokardiografia Fiegenbauma, Eds.: Fiegenbaum H, Armstrong WF, Ryan T. Medipage Warszawa 2006, 757-797.
17. Ward KM, Binns H, Chin C, Webber SA, Canter CE, Pahl E: Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 2004, 23, 1040-1045. (Pubitemid 39345647)
18. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C, Cipolla C: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010, 55, 213-220.
19. Jurado J, Thopmson PD: Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer 2005, 44, 620-624. (Pubitemid 40629211)
20. Ziółkowska E, Woźniak-Wiśniewska A, Wiśniewski T, Makarewicz R, Sinkiewicz W: The influence of radiotherapy on cardiac disorders. Współcz Onkol 2009, 13, 16-12.
21. Hensley ML, Schuchter LM, Lindley C. Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG: American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999, 17, 3333-3355. (Pubitemid 29471562)
22. Lipshultz SE: Exposure to Anthracyclines during childhood causes cardiac injury. Semin Oncol 2006, 33, 3 Suppl. 8, S8-14.
23. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010, 11, 950-961.
24. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002, 20, 2895-2903.
25. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114, 2474-2478.
26. Lipshultz SE: Ventricular dysfunction clinical research in infants, children and adolescents. Progress Pediatr Cardiol 2000, 12, 1-28.
27. Bu'Lock FA, Mott MG, Oakhill A, Martin RP: Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996, 75, 416-422.
28. Temming P, Qureshi A, Hardt J, Leiper AD, Levitt G, Ancliff PJ, Webb DK: Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer 2011, 56, 625-630.
29. van der Pal HJ, van Dalen EC, Hauptmann M, Kok WE, Caron HN, van den Bos C, Oldenburger F, Koning CC, van Leeuwen FE, Kremer LC: Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010, 170, 1247-1255.
30. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23, 2629-2636. (Pubitemid 46179451)
31. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
32. ACC/AHA/ASE 2003 Guideline update for the Clinical Application of Echocardiography: summary article - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003, 42, 954-970.
33. Hamm CW, Heeschen Ch, Falk E: Ostre zespoły wieńcowe. In: Choroby serca i naczyń, Eds.: Camm AJ, Luoscher TF, Serruys PW. Termedia Wydawnictwo Medyczne, Poznań 2006, 349-383.
34. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ottlinger ME: Predictive value of cardiactroponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96, 2641-2648. (Pubitemid 27451357)
35. Cowie MR, Mendez GF: BNP and congestive heart failure. Prog Cardiovasc Dis 2002, 44, 293-321. (Pubitemid 34438288)
36. McMurray J, Komajda M, Anker S: Niewydolność serca: epidemiologia, patofizjologia i rozpoznanie. In: Choroby serca i naczyń, Eds.: Camm AJ, Luoscher TF, Serruys PW. Termedia Wydawnictwo Medyczne, Poznań 2006, 723-759.
37. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, Leon M, Civelli M, Martinelli G, Cipolla CM: N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005, 51, 1405-1410. (Pubitemid 41060872)
38. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, Kurabayashi M, Yamaoki K, Mitani K, Hirai H, Nagai R, Yazaki Y: Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136, 362-363. (Pubitemid 28368863)
39. Long-term follow-up guidelines from the Children's Oncology Group available online at www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf, accessed January 19, 2010.
40. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992, 20, 62-69.
41. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID: Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003, 97, 1991-1998. (Pubitemid 36397277)